Peter Blume Jensen Acrivon Therapeutics, Inc. (ACRV) insider trading activity

Shares Held (Direct Ownership) 2.34M

3.29% 3M change

11.88% 12M change

Total Value Held N/A

Peter Blume-Jensen Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 21 2024	SELL Payment of exercise price or tax liability	$128,220 $6.44 p/Share	19,910 Reduced 0.84%	2,342,837 Common Stock
Nov 14 2024	SELL Payment of exercise price or tax liability	$473,346 $7.92 p/Share	59,766 Reduced 2.47%	2,362,747 Common Stock
Aug 21 2024	SELL Payment of exercise price or tax liability	$731,671 $9.19 p/Share	79,616 Reduced 3.18%	2,422,513 Common Stock
Aug 14 2024	SELL Payment of exercise price or tax liability	$419,550 $7.02 p/Share	59,765 Reduced 2.33%	2,502,129 Common Stock
May 14 2024	SELL Payment of exercise price or tax liability	$459,114 $8.36 p/Share	54,918 Reduced 2.1%	2,561,894 Common Stock
Feb 14 2024	SELL Payment of exercise price or tax liability	$142,327 $3.4 p/Share	41,861 Reduced 1.57%	2,616,812 Common Stock
Nov 14 2023	SELL Payment of exercise price or tax liability	$1,214,236 $5.08 p/Share	239,023 Reduced 8.25%	2,658,673 Common Stock
Aug 21 2023	BUY Grant, award, or other acquisition	-	493,994 Added 14.56%	2,897,696 Common Stock
May 31 2023	BUY Exercise of conversion of derivative security	$130,387 $3.88 p/Share	33,605 Added 1.38%	2,403,702 Common Stock
Nov 14 2022	BUY Grant, award, or other acquisition	-	1,498,240 Added 38.73%	2,370,097 Common Stock

President and CEO

Watertown, MA

Receive a notification when an Institution or Guru buys or sells ACRV shares.

Notify only if

Value

Get notified when an Acrivon Therapeutics, Inc. insider buys or sells ACRV shares.

Notify only if

Operation

Value

Type

Receive news related to Acrivon Therapeutics, Inc.